These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 314001)
41. Paranoid versus nonparanoid schizophrenia and long-term hospital treatment outcome. Allen JG; Tarnoff G; Kearns NW; Coyne L Bull Menninger Clin; 1986 Jul; 50(4):341-50. PubMed ID: 3742120 [No Abstract] [Full Text] [Related]
42. Schizophrenia: a multinational study. Units of analysis, groups of units, and the psychopathology of patient groups. Public Health Pap; 1975; (63):46-78. PubMed ID: 1242839 [No Abstract] [Full Text] [Related]
43. [Various results of an epidemiologic study of paranoid schizophrenia]. Alimkhanov ZhA Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(8):1206-12. PubMed ID: 4050234 [TBL] [Abstract][Full Text] [Related]
44. [Study of HLA antigens in paranoid schizophrenia]. Goudemand M; Goudemand J; Fontan M Lille Med; 1979 Feb; 24(2):78-81. PubMed ID: 431319 [No Abstract] [Full Text] [Related]
45. [Comparative studies of the effects of perazine, fluphenazine, trifluoperazine, chlorpromazine and haloperidol on primary and deficit symptoms of paranoid schizophrenia]. Termińska K; Mrowiec W Psychiatr Pol; 1989; 23(1):24-30. PubMed ID: 2573098 [TBL] [Abstract][Full Text] [Related]
46. [Favorable outcomes of paranoid schizophrenia]. Orlova VA Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(1):74-81. PubMed ID: 6702381 [TBL] [Abstract][Full Text] [Related]
47. [Some aspects of the depressive-paranoid syndrome encountered in schizophrenia]. Grecu G; Csiky K Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1977; 22(4):267-73. PubMed ID: 609862 [No Abstract] [Full Text] [Related]
48. [Depressive symptoms in active phase of paranoid schizophrenia. Part I: Their link to negative symptoms]. Karakuła H; Grzywa A Psychiatr Pol; 1998; 32(1):15-23. PubMed ID: 9594580 [TBL] [Abstract][Full Text] [Related]
49. [Own experiences (1989-1994) in the treatment of adolescent schizophrenic paranoid syndromes with Leponex produced by Sandoz company]. Abczyńska M; Kaźmirek Z; Syguda J; Termińska K Psychiatr Pol; 1995; 29(1):79-85. PubMed ID: 7878157 [TBL] [Abstract][Full Text] [Related]
50. [Body to body nurse-patient]. Robin S Soins Psychiatr; 2001; (213):19-23. PubMed ID: 11949397 [No Abstract] [Full Text] [Related]
51. A special coincidence of erotomania and Fregoli syndrome. Brüggemann BR; Garlipp P Psychopathology; 2007; 40(6):468. PubMed ID: 17848830 [No Abstract] [Full Text] [Related]
52. [Experiences with so-called guest-patients--a special form of clinical night-care]. Eicke WJ Nervenarzt; 1973 Jun; 44(6):327-8. PubMed ID: 4723615 [No Abstract] [Full Text] [Related]
53. [Palmar dermatoglyphics in different phenotypic manifestations of schizophrenia]. Dvirskiĭ AE Tsitol Genet; 1975; 9(3):195-200. PubMed ID: 1221570 [TBL] [Abstract][Full Text] [Related]
54. [Treatment-related relapses in paranoid schizophrenia]. Smoczyński S Psychiatr Pol; 1973; 7(3):247-54. PubMed ID: 4728442 [No Abstract] [Full Text] [Related]
55. [Analysis of errors in the transformation of abstract concepts by patients with paranoid schizophrenia]. Grzywa A; Chlewiński Z Psychiatr Pol; 1984; 18(4):333-8. PubMed ID: 6536018 [No Abstract] [Full Text] [Related]
56. [Effectiveness of eglonyl (sulpiride) in the treatment of paranoid schizophrenia (preliminary report)]. Czerwiński A; Chłopocka-Woźniak M Psychiatr Pol; 1978; 12(2):173-8. PubMed ID: 662981 [No Abstract] [Full Text] [Related]
57. Correlates of personality organization in schizophrenic patients. Fabrega H; Fabrega H; Swartz JD J Nerv Ment Dis; 1968 Feb; 146(2):127-35. PubMed ID: 5652830 [No Abstract] [Full Text] [Related]